Page 1856 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 107 Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies 1649.e3

82. MacMillan ML, Weisdorf DJ, Brunstein CG, et al: Acute graft-versus- 99. Ponce DM, Gonzales AM, Lubin M, et al: Successful Treatment of
host disease after unrelated donor umbilical cord blood transplantation: Acute Gastrointestinal (GI) Graft-Versus-Host Disease (GVHD) After
analysis of risk factors. Blood 113(11):2410–2415, 2009. Cord Blood Transplantation (CBT) With Single Agent Budesonide.
83. Rodrigues CA, Sanz G, Brunstein CG, et al: Analysis of risk factors Biol Blood Marrow Transplant 17(2):S342–S343, 2011.
for outcomes after unrelated cord blood transplantation in adults 100. Weisdorf D, Eapen M, Ruggeri A, et al: Alternative donor trans-
with lymphoid malignancies: a study by the Eurocord-Netcord and plantation for older patients with acute myeloid leukemia in first
lymphoma working party of the European group for blood and marrow complete remission: a center for international blood and marrow
transplantation. J Clin Oncol 27(2):256–263, 2009. transplant research-eurocord analysis. Biol Blood Marrow Transplant
84. Lindemans CA, Chiesa R, Amrolia PJ, et al: Impact of thymoglobulin 20(6):816–822, 2014.
prior to pediatric unrelated umbilical cord blood transplantation on 101. Rodrigues CA, Rocha V, Dreger P, et al: Alternative donor hematopoi-
immune reconstitution and clinical outcome. Blood 123(1):126–132, etic stem cell transplantation for mature lymphoid malignancies after
2014. reduced-intensity conditioning regimen: similar outcomes with umbili-
85. Cutler C, Stevenson K, Kim HT, et al: Double umbilical cord blood cal cord blood and unrelated donor peripheral blood. Haematologica
transplantation with reduced intensity conditioning and sirolimus- 99(2):370–377, 2014.
based GVHD prophylaxis. Bone Marrow Transplant 46(5):659–667, 102. Marks DI, Woo KA, Zhong X, et al: Unrelated umbilical cord blood
2011. transplant for adult acute lymphoblastic leukemia in first and second
86. Jacobson CA, Turki AT, McDonough SM, et al: Immune reconstitution complete remission: a comparison with allografts from adult unrelated
after double umbilical cord blood stem cell transplantation: comparison donors. Haematologica 99(2):322–328, 2014.
with unrelated peripheral blood stem cell transplantation. Biol Blood 103. Kai S, Wake A, Okada M, et al: Double-unit cord blood transplanta-
Marrow Transplant 18(4):565–574, 2012. tion after myeloablative conditioning for patients with hematologic
87. Brunstein CG, Weisdorf DJ, DeFor T, et al: Marked increased risk of malignancies: a multicenter phase II study in Japan. Biol Blood Marrow
Epstein-Barr virus-related complications with the addition of antithy- Transplant 19(5):812–819, 2013.
mocyte globulin to a nonmyeloablative conditioning prior to unrelated 104. Arcese W: Myeloablative versus Reduced Intensity Conditioning Regimen
umbilical cord blood transplantation. Blood 108(8):2874–2880, 2006. Cord Blood Transplants. Paper presented at: 37th Annual Meeting of the
88. Majhail NS, Brunstein CG, Tomblyn M, et al: Reduced-intensity EGBMT; April 4, 2011, 2011; Paris.
allogeneic transplant in patients older than 55 years: unrelated umbilical 105. Tucunduva L, Ruggeri A, Sanz G, et al: Impact of Myeloablative and
cord blood is safe and effective for patients without a matched related Reduced Intensity Conditioning on Outcomes After Unrelated Cord
donor. Biol Blood Marrow Transplant 14(3):282–289, 2008. Blood Transplantation for Adults with Acute Lymphoblastic Leukemia.
89. Brunstein CG, Fuchs EJ, Carter SL, et al: Alternative donor trans- Biol Blood Marrow Transplant 19(2):S127, 2013.
plantation after reduced intensity conditioning: results of parallel 106. Gutman JA, Leisenring W, Appelbaum FR, et al: Low relapse without
phase 2 trials using partially HLA-mismatched related bone marrow or excessive transplant-related mortality following myeloablative cord blood
unrelated double umbilical cord blood grafts. Blood 118(2):282–288, transplantation for acute leukemia in complete remission: a matched
2011. cohort analysis. Biol Blood Marrow Transplant 18(9):1122–1129, 2009.
90. Brunstein CG, Eapen M, Ahn KW, et al: Reduced-intensity condition- 107. Brunstein CG, Gutman JA, Weisdorf DJ, et al: Allogeneic hematopoi-
ing transplantation in acute leukemia: the effect of source of unrelated etic cell transplantation for hematologic malignancy: relative risks and
donor stem cells on outcomes. Blood 119(23):5591–5598, 2012. benefits of double umbilical cord blood. Blood 116(22):4693–4699,
91. Chen YB, Aldridge J, Kim HT, et al: Reduced-intensity condition- 2010.
ing stem cell transplantation: comparison of double umbilical cord 108. Konuma T, Kato S, Ooi J, et al: Comparable long-term outcome of
blood and unrelated donor grafts. Biol Blood Marrow Transplant unrelated cord blood transplantation with related bone marrow or
18(5):805–812, 2012. peripheral blood stem cell transplantation in patients aged 45 years or
92. Robin M, Ruggeri A, Labopin M, et al: Comparison of unrelated older with hematologic malignancies after myeloablative conditioning.
cord blood and peripheral blood stem cell transplantation in adults Biol Blood Marrow Transplant 20(8):1150–1155, 2014.
with myelodysplastic syndrome after reduced-intensity conditioning 109. Liu HL, Sun ZM, Geng LQ, et al: Similar survival, but better quality
regimen: a collaborative study from Eurocord (Cord blood Committee of life after myeloablative transplantation using unrelated cord blood vs
of Cellular Therapy & Immunobiology Working Party of EBMT) and matched sibling donors in adults with hematologic malignancies. Bone
Chronic Malignancies Working Party. Biol Blood Marrow Transplant Marrow Transplant 49(8):1063–1069, 2014.
21(3):489–495, 2015. 110. Fanning LR, Hegerfeldt Y, Tary-Lehmann M, et al: Allogeneic
93. Rodrigues CA, Rocha V, Dreger P, et al: Alternative donor hematopoi- transplantation of multiple umbilical cord blood units in adults: role
etic stem cell transplantation for mature lymphoid malignancies after of pretransplant-mixed lymphocyte reaction to predict host-vs-graft
reduced-intensity conditioning regimen: similar outcomes with umbili- rejection. Leukemia 22(9):1786–1790, 2008.
cal cord blood and unrelated donor peripheral blood. Haematologica 111. Brunstein CG, Barker JN, Weisdorf DJ, et al: Intra-BM injection
99(2):370–377, 2014. to enhance engraftment after myeloablative umbilical cord blood
94. Warlick ED, Peffault de Latour R, Shanley R, et al: Allogeneic hema- transplantation with two partially HLA-matched units. Bone Marrow
topoietic cell transplantation outcomes in acute myeloid leukemia: Transplant 43(12):935–940, 2009.
similar outcomes regardless of donor type. Biol Blood Marrow Transplant 112. Frassoni F, Gualandi F, Podesta M, et al: Direct intrabone transplant of
21(2):357–363, 2015. unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet
95. Cutler C, Ballen K: Reduced-intensity conditioning and umbili- Oncol 9(9):831–839, 2008.
cal cord blood transplantation in adults. Bone Marrow Transplant 113. Bautista G, Cabrera JR, Regidor C, et al: Cord blood transplants sup-
44(10):667–671, 2009. ported by co-infusion of mobilized hematopoietic stem cells from a
96. Thomson BG, Robertson KA, Gowan D, et al: Analysis of engraftment, third-party donor. Bone Marrow Transplant 43(5):365–373, 2009.
graft-versus-host disease, and immune recovery following unrelated 114. Liu H, Rich ES, Godley L, et al: Reduced-intensity conditioning
donor cord blood transplantation. Blood 96(8):2703–2711, 2000. with combined haploidentical and cord blood transplantation results
97. Soiffer RJ, Lerademacher J, Ho V, et al: Impact of immune modula- in rapid engraftment, low GVHD, and durable remissions. Blood
tion with anti-T-cell antibodies on the outcome of reduced-intensity 118(24):6438–6445, 2011.
allogeneic hematopoietic stem cell transplantation for hematologic 115. de Lima M, McMannis J, Gee A, et al: Transplantation of ex vivo
malignancies. Blood 117(25):6963–6970, 2011. expanded cord blood cells using the copper chelator tetraethyl-
98. Sauter C, Abboud M, Jia X, et al: Serious infection risk and immune enepentamine: a phase I/II clinical trial. Bone Marrow Transplant
recovery after double-unit cord blood transplantation without antithy- 41(9):771–778, 2008.
mocyte globulin. Biol Blood Marrow Transplant 17(10):1460–1471, 116. Stiff PJ, Montesinos P, Peled T, et al: StemEx®(Copper Chelation Based)
2011. Ex Vivo Expanded Umbilical Cord Blood Stem Cell Transplantation